Ideaya Biosciences Inc [IDYA] stock prices are up 3.41% to $46.36 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The IDYA shares have gain 4.02% over the last week, with a monthly amount glided 6.35%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, March 2024, IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events. In a post published today on Yahoo Finance, IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.
From an analyst’s perspective:
Ideaya Biosciences Inc [NASDAQ: IDYA] stock has seen the most recent analyst activity on August 08, 2023, when SVB Securities initiated its Outperform rating and assigned the stock a price target of $33. Previously, Goldman started tracking the stock with Buy rating on May 24, 2023, and set its price target to $32. On April 24, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $24 on the stock. Berenberg started tracking the stock assigning a Buy rating and suggested a price target of $26 on March 23, 2023. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $25 as its price target on February 28, 2023. CapitalOne started tracking with a Overweight rating for this stock on December 28, 2022, and assigned it a price target of $29. In a note dated October 27, 2022, Citigroup initiated an Buy rating and provided a target price of $26 on this stock.
The stock price of Ideaya Biosciences Inc [IDYA] has been fluctuating between $13.29 and $47.74 over the past year. Currently, Wall Street analysts expect the stock to reach $24.75 within the next 12 months. Ideaya Biosciences Inc [NASDAQ: IDYA] shares were valued at $46.36 at the most recent close of the market. An investor can expect a potential drop of -46.61% based on the average IDYA price forecast.
Analyzing the IDYA fundamentals
The Ideaya Biosciences Inc [NASDAQ:IDYA] reported sales of 23.39M for trailing twelve months, representing a drop of -2.46%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -5.75%, Pretax Profit Margin comes in at -4.83%, and Net Profit Margin reading is -4.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.22 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.19 points at the first support level, and at 44.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 47.62, and for the 2nd resistance point, it is at 48.89.
Ideaya Biosciences Inc [IDYA] reported earnings per share of -$0.52 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.47/share, meaning a difference of -$0.05 and a surprise factor of -10.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.46 per share as compared to estimates of -$0.49 per share, a difference of $0.03 representing a surprise of 6.10%.
Ratios To Look Out For
It’s worth pointing out that Ideaya Biosciences Inc [NASDAQ:IDYA]’s Current Ratio is 19.65. On the other hand, the Quick Ratio is 19.65, and the Cash Ratio is 5.79. Considering the valuation of this stock, the price to sales ratio is 146.06, the price to book ratio is 4.85.
Transactions by insiders
Recent insider trading involved Hata Yujiro S, President and CEO, that happened on Feb 09 ’24 when 23557.0 shares were sold., Ruiz Briseno Andres completed a deal on Feb 09 ’24 to sell 2000.0 shares. Meanwhile, President and CEO Hata Yujiro S sold 75815.0 shares on Feb 08 ’24.
